#### (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

### (19) World Intellectual Property Organization International Bureau



# 

## (43) International Publication Date 31 July 2003 (31.07.2003)

PCT

## (10) International Publication Number WO 03/061645 A1

(51) International Patent Classification7: A61K 31/196, A61P 29/00

WOOD, Jeanette, Marjorie [NZ/CH]; In den Kleematten 18, CH-4105 Biel-Benken (CH).

(21) International Application Number: PCT/EP03/00612

(74) Agent: GROS, Florent; Novartis AG, Corporate Intellectual Property, Patent and Trademark Department, CH-4002 Basel (CH).

(22) International Filing Date: 22 January 2003 (22.01.2003)

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR. HU. ID. IL. IN. IS. JP. KE. KG. KP. KR. KZ. LC. LK. LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT,

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0201520.4

23 January 2002 (23.01.2002) GB

(71) Applicant (for all designated States except AT, US): NO-VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(84) Designated States (regional): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR).

UA, US, UZ, VC, VN, YU, ZA, ZW.

(71) Applicant (for AT only): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, 1235 Vienna (AT).


#### Published:

(72) Inventors; and

- with international search report
- (75) Inventors/Applicants (for US only): BRAZZELL, Romulus, Kimbro [US/US]; 9705 Foxworth Drive, Alpharetta, GA 30201 (US). LAMBROU, George, N. [FR/FR]; 76, rue de Mulhouse, F-68300 St. Louis (FR). LATOUR, Elisabeth [FR/FR]; 26F, rue de Bâle, F-68870 Bartenheim-La Chaussée (FR). OTTLECZ, Anna [US/CH]; Pilgerstrasse 16, CH-4055 Basel (CH).
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

#### (54) Title: PHARMACEUTICAL USE OF COX-2 INHIBITORS IN ANGIOGENESIS-MEDIATED OCULAR DISORDERS



(57) Abstract: The invention provides a method of treating an angiogenesis-mediated ocular disorder, e.g. ocular neovascularisation, retinal neovascularisation, including neovascularisation following injury or infection, retrolental fibroplasias, and neovascular glaucoma, age-related macular degeneration, diabetic retinopathy, pathologic myopia, ocular histoplasmosis, neovascular glaucoma, retinopathy of prematurity, the after effects of corneal transplantation, control of postsurgical ocular inflammation (e.g. after cataract surgery), cystoid macular edema (CME), herpes keratitis, in a subject in need of such treatment which comprises administering to the subject an effective amount of a COX-2 inhibitor of formula I wherein R, R1, R2, R3, R4, and R5 are as defined; a pharmaceutically acceptable salts thereof; or a pharmaceutically acceptable prodrug esters thereof.